Sugi Predict

Sugi Predict / Compounds / SCHEMBL275869

SCHEMBL275869

SCHEMBL275869

O=C1N=Cc2cc(-c3cnc(NC4CCC4)c4ncnn34)ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPKAPK5 Q8IW41 3/20 0.42
▸ TTK P33981 1/20 0.37
▸ EGLN2 Q96KS0 1/20 0.34
▸ TP53 P04637 5/20 0.33
▸ LMNA P02545 4/20 0.33
▸ BRD4 O60885 4/20 0.33
▸ ATAD2 Q6PL18 4/20 0.33
▸ MAPT P10636 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ NFKB1 P19838 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ NFKB2 Q00653 1/20 0.33
▸ RELA Q04206 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL274498 0.98 MAPKAPK5 (0.42) MAPKAPK5TTKEGLN2TP53LMNA
SCHEMBL273763 0.97 MAPKAPK5 (0.41) MAPKAPK5TTKEGLN2TP53LMNA
SCHEMBL275491 0.96 MAPKAPK5 (0.43) MAPKAPK5TTKEGLN2BRD4ATAD2
SCHEMBL274671 0.94 MAPKAPK5 (0.42) MAPKAPK5TTKBRD4ATAD2ALDH1A1
SCHEMBL275197 0.92 MAPKAPK5 (0.40) MAPKAPK5TTKEGLN2CD38
SCHEMBL273771 0.92 MAPKAPK5 (0.47) MAPKAPK5TTKMAPK1CD38MKNK1
SCHEMBL274887 0.83 MAPKAPK5 (0.40) MAPKAPK5TTKEGLN2MKNK1
SCHEMBL275911 0.82 FLT3 (0.43) MAPKAPK5TTKADORA3
SCHEMBL275870 0.82 MAPKAPK5 (0.62) MAPKAPK5MAPK1MKNK1
SCHEMBL275076 0.80 FLT3 (0.42) MAPKAPK5TTKADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133895-B2 Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases JANSSEN PHARMACEUTICA N.V. (BE) 2012-03-13 — — US claimed
US-20090131446-A1 Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases GALAPAGOS, N.V. (BE) 2009-05-21 — — US claimed
US-8138193-B2 Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases JANSSEN PHARMACEUTICA N.V. (BE) 2012-03-20 — — US disclosed
US-8133895-B2 Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases JANSSEN PHARMACEUTICA N.V. (BE) 2012-03-13 — — US disclosed
US-20100240666-A1 FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ANDREWS MARTIN JAMES INGLIS 2010-09-23 — — US disclosed
US-20090131446-A1 Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases GALAPAGOS, N.V. (BE) 2009-05-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131446-A1 Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases NOD1, TNF, NOD2 MAPKAPK5 1247/4885TTK 4697/4885EGLN2 2621/4885
US-20100240666-A1 FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES RRP15, RARS2, RO60 MAPKAPK5 1958/4885TTK 4724/4885EGLN2 3330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.